Literature DB >> 20424813

[Difficulties in pharmacotherapy of the elderly].

H Burkhardt1, M Wehling.   

Abstract

Pharmacotherapy in the elderly is a challenge as the real risk-benefit ratio of many drugs and treatment strategies often remains unknown in these patients. Furthermore there are some special adverse drug reactions such as falls and delirium not only occurring more often but also causing an increased proportion of adverse outcomes. Finally there is the phenomenon of multimorbidity and polypharmacy responsible for treatment errors and inadequate drug treatment. A comprehensive risk-benefit analysis is needed to avoid both under- and over-treatment. This analysis should cover patients preferences, vulnerability, resources and functionality. Some simple treatment rules may improve drug treatment in the elderly, but an improved characterization of drugs and treatment strategies with regard to the elderly is essential.

Entities:  

Mesh:

Year:  2010        PMID: 20424813     DOI: 10.1007/s00108-010-2582-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  7 in total

1.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.

Authors:  Donna M Fick; James W Cooper; William E Wade; Jennifer L Waller; J Ross Maclean; Mark H Beers
Journal:  Arch Intern Med       Date:  2003 Dec 8-22

2.  [Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA].

Authors:  M Wehling
Journal:  Dtsch Med Wochenschr       Date:  2008-10-22       Impact factor: 0.628

3.  The Timed Test of Money Counting: a short physical performance test for manual dexterity and cognitive capacity.

Authors:  T Nikolaus; M Bach; N Specht-Leible; P Oster; G Schlierf
Journal:  Age Ageing       Date:  1995-05       Impact factor: 10.668

Review 4.  Optimising drug treatment for elderly people: the prescribing cascade.

Authors:  P A Rochon; J H Gurwitz
Journal:  BMJ       Date:  1997-10-25

5.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

6.  Elderly patients' problems with medication. An in-hospital and follow-up study.

Authors:  T Nikolaus; W Kruse; M Bach; N Specht-Leible; P Oster; G Schlierf
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

7.  Unrecognized delirium in ED geriatric patients.

Authors:  L M Lewis; D K Miller; J E Morley; M J Nork; L C Lasater
Journal:  Am J Emerg Med       Date:  1995-03       Impact factor: 2.469

  7 in total
  5 in total

Review 1.  Reducing Polypharmacy from the Perspectives of General Practitioners and Older Patients: A Synthesis of Qualitative Studies.

Authors:  Beate Bokhof; Ulrike Junius-Walker
Journal:  Drugs Aging       Date:  2016-04       Impact factor: 3.923

Review 2.  [Drug-drug interactions in the elderly : Which ones really matter?].

Authors:  K Bitter; J F Schlender; R Woltersdorf
Journal:  Internist (Berl)       Date:  2016-07       Impact factor: 0.743

3.  Healthcare Provider Perspectives on Digital and Interprofessional Medication Management in Chronically Ill Older Adults of Turkish Descent in Germany: A Qualitative Structuring Content Analysis.

Authors:  Rona Bird; Ilknur Özer-Erdogdu; Meryem Aslan; Hürrem Tezcan-Güntekin
Journal:  Front Public Health       Date:  2022-06-02

Review 4.  [Strategies of age-adapted pharmacotherapy in renal failure].

Authors:  R Lenssen; A Liekweg
Journal:  Z Gerontol Geriatr       Date:  2016-07-22       Impact factor: 1.281

5.  General practitioners' views on polypharmacy and its consequences for patient health care.

Authors:  Juliane Köberlein; Mandy Gottschall; Kathrin Czarnecki; Alexander Thomas; Antje Bergmann; Karen Voigt
Journal:  BMC Fam Pract       Date:  2013-08-15       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.